Scientists are making inroads because thousands of people with Parkinson’s and their family members have donated their brains to science, including to PDF-supported programs at Columbia University Medical Center and Rush University Medical Center.
PDF Grant Programs
Are you interested in furthering Parkinson's science? View PDF's open grant programs.
Controlled iontophoretic delivery of pramipexole: Electrotransport kinetics in vitro and in vivo.
PDF's targeted PubMed search provides you with access to journal articles from the last 90 days that may be pertinent to Parkinson's disease research.
Not what you're looking for? Do you need informational publications about Parkinson's targeted for people living with Parkinson's, caregivers and family members? Please browse PDF's educational materials and programs - which are all available electronically or in print. Order for yourself, a loved one or in bulk for your patients or support group.
Eur J Pharm Biopharm 2014 Feb;
Authors: Dhaval R Kalaria, Pratikkumar Patel, Virginia Merino, Vandana B Patravale, Yogeshvar N Kalia
The objective of the study was to investigate the anodal iontophoretic delivery of pramipexole (PRAM), a dopamine agonist used for the treatment of Parkinson's disease, in order to determine whether therapeutic amounts of the drug could be delivered across the skin. Preliminary iontophoretic experiments were performed in vitro using porcine ear and human abdominal skin. These were followed by a pharmacokinetic study in male Wistar rats to determine the drug input rate in vivo. Stability studies revealed that after current application (0.5mA/cm(2) for 6h), the solution concentration of PRAM was only 60.2±5.3% of its initial value. However, inclusion of sodium metabisulfite (0.5%), an antioxidant, increased this to 97.2±3.1%. Iontophoretic transport of PRAM across porcine skin in vitro was studied as a function of current density (0.15, 0.3, 0.5mA/cm(2)) and concentration (10, 20, 40mM). Increasing the current density from 0.15 to 0.3 and 0.5mA/cm(2), resulted in 2.5- and 4-fold increases in cumulative permeation, from 309.5±80.2 to 748.8±148.1 and 1229.1±138.6?g/cm(2), respectively. Increasing the PRAM concentration in solution from 10 to 20 and 40mM resulted in a 2-fold increase in cumulative permeation (816.4±123.3, 1229.1±138.6 and 1643.6±201.3?g/cm(2), respectively). Good linearity was observed between PRAM flux and both the applied current density (r(2)=0.98) and drug concentration in the formulation (r(2)=0.99). Co-iontophoresis of acetaminophen showed that electromigration was the dominant electrotransport mechanism (accounting for >80% of delivery) and that there was no inhibition of electroosmotic flow at any current density. Cumulative iontophoretic permeation across human and porcine skin (after 6h at 0.5mA/cm(2)) was also shown to be statistically equivalent (1229.1±138.6 and 1184.8±236.4?g/cm(2), respectively). High transport and delivery efficiencies were achieved for PRAM (up to 7% and 58%, respectively). The plasma concentration profiles obtained in the iontophoretic studies in vivo (20mM PRAM; 0.5mA/cm(2) for 5h) were modelled using constant and time-variant input models; the latter gave a superior quality fit. The drug input rate in vivo suggested that PRAM electrotransport rates would be sufficient for therapeutic delivery and the management of Parkinsonism.
PMID: 24525072 [PubMed - as supplied by publisher]